



November 22, 2016

Accelerate Diagnostics to Present at the Piper Jaffray 28th Annual Healthcare Conference on November 30th

TUCSON, Ariz., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today that Lawrence Mehren, President and Chief Executive Officer, is scheduled to present at the Piper Jaffray 28th Annual Healthcare Conference in New York City, NY on Wednesday, November 30th at 2:00 PM EST.

A live audio webcast of the presentation will be accessible from the investor portal of the company's website at <http://ir.axdx.com/>.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. ("Accelerate Diagnostics") (Nasdaq:AXDX), is an *in vitro* diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and hospital acquired infections. The company's fully automated system, the Accelerate Pheno™ system, and direct from positive blood culture test, the Accelerate PhenoTest™ BC kit, leverage a suite of technologies to reduce the lengthy culture and sample preparation steps required prior to testing. Using proprietary molecular and phenotypic detection methods, the solution aims to reduce the time that clinicians must wait for quantitative antimicrobial susceptibility results necessary for optimal antibiotic selection, dosing, and infusion strategy, called minimum inhibitory concentrations, or MICs. The Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit are currently under review by the U.S. Food and Drug Administration.

Visit axdx.com to get more information about Accelerate Diagnostics and its products and technologies.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, about our projections as to when certain key business milestones may be achieved, including obtaining marketing authorization by the FDA of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the commercial launch of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the potential of our technology, the growth of the market, our estimates as to the size of our market opportunity and potential pricing, our competitive position and estimates of time reduction to results, and our future development plans and growth strategy. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 9, 2016. In addition, the company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.

Investors May Contact:

Laura Pierson, Accelerate Diagnostics, +1 520 365-3100

investors@axdx.com

Reporters May Contact:

Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100

achasteen@axdx.com

Source: Accelerate Diagnostics, Inc.

News Provided by Acquire Media